Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 21 sources its claims cite were checked for support.

Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models

Open access

Abstract

Retinal gene therapy using dual adeno-associated viral (AAV) intein vectors can be applied to genetic forms of blindness caused by mutations in genes with coding sequences that exceed single AAV cargo capacity, such as Stargardt disease (STGD1), the most common inherited macular dystrophy. In view of clinical translation of dual AAV intein vectors, here we set to evaluate both the efficiency and safety of their subretinal administration in relevant large animal models. Accordingly, we have developed the first pig model of STGD1, which we found to accumulate lipofuscin similarly to patients. This accumulation is significantly reduced upon subretinal administration of dual AAV intein vectors whose safety and pharmacodynamics we then tested in nonhuman primates, which showed modest and reversible inflammation as well as high levels of photoreceptor transduction. This bodes well for further clinical translation of dual AAV intein vectors in patients with STGD1 as well as for other blinding diseases that require the delivery of large genes.

Overview

CoChat Summary

TL;DR

Dual AAV intein vectors delivering ABCA4 were tested in a newly generated STGD1 pig model and in nonhuman primates. Subretinal administration reconstituted ABCA4, reduced lipofuscin in pigs, and showed high photoreceptor transduction with modest, largely reversible inflammation in NHPs.

Key findings

  • A pig STGD1 model was generated by SCNT from Cas9-edited fibroblasts; ABCA4 protein was absent in retinas, and increased RPE lipofuscin was present from 8.5 months, with significant A2E accumulation (*P < 0.001, Welch’s t test) and significantly reduced photopic ERG at 2–3 years.
  • In STGD1 pigs, subretinal AAV8.ABCA4.intein vectors (1 × 10^11 GC of each vector per bleb) restored ABCA4 protein to band intensities similar to WT and reduced lipofuscin in treated areas, reaching statistical significance in the highest-transduction areas of pigs treated at 2 years (*P < 0.05).
  • In NHPs, AAV8.ABCA4.intein vectors at low dose (1.8 × 10^11 total GC/eye) or high dose (5.6 × 10^11 total GC/eye) transduced 76–99% of photoreceptors in high-transduction regions, spanning on average 61% (range 56–69%) of analyzed retinal sections, with almost total photoreceptor cotransduction.
  • NHP ABCA4 protein levels in treated retina punches were on average ~40% above endogenous levels in FB-treated control eyes; ocular inflammation was modest and dose-dependent, with ERG recovery largely complete by week 13 in low-dose eyes and partially complete in high-dose eyes.

Methods

  • STGD1 pigs were generated via SCNT from fibroblasts with CRISPR-Cas9 frameshift mutations in ABCA4 exon 2; phenotype was characterized by genotyping, Western blot, retinal histology/fluorescence for lipofuscin and ONL thickness, HPLC for A2E, and ERG.
  • Therapeutic efficacy in pigs used subretinal injection of AAV8.GRK1-ABCA4.intein vectors plus AAV8.GRK1-EGFP, with contralateral FB/EGFP control eyes; eyes were harvested 2 months postinjection for Western blot and lipofuscin quantification.
  • NHP safety/expression study used 11 female cynomolgus macaques in a 13-week toxicokinetic design with subretinal FB, low-dose, or high-dose AAV8.ABCA4.intein vectors; assessments included ophthalmic examination, ERG, VEP, IOP, fundus photography, OCT, histopathology, BaseScope for intein mRNA, and Simple Western for ABCA4 protein.

Limitations

  • The paper states that limited pig numbers prevented definitive conclusions from A2E HPLC and ERG in injected eyes; ERG showed high variability, and eye harvesting/storage in CO2-independent media for 6–10 hours caused a substantial drop in A2E levels even in FB-injected eyes.
  • The paper states that the pig efficacy study used aged animals (2–3 years) with ongoing lipofuscin accumulation from at least 8.5 months, a short 2-month postinjection interval, and AAV8, which reaches a transduction plateau only after 7 weeks; whether longer ABCA4 expression in younger pigs could fully normalize lipofuscin remains unknown.
  • The paper states the NHP study was not compliant with Good Laboratory Practice, though performed according to scientifically sound principles; the text also makes evident that NHP groups were small (e.g., n = 7 per AAV dose, n = 8 FB) and that some analyses had limited n.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.adt9354

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Characterization of the STGD1 pig model. (A) Western blot analysis to assess ABCA4 levels in STGD1 (KO) pig retinas derived from different fibroblasts clones. The ID of the clones is indicated above each lane. WT, wild-type. (B) Representative images of retinal cryosections from WT and KO pigs at 10 months of age, showing intense lipofuscin accumulation (red autofluorescence in the RPE layer), in the absence of evident retinal degeneration. RPE, retinal pigment epithelium; ONL, outer nuclear layer; INL, inner nuclear layer. (C) Quantification of lipofuscin accumulation in KO pig retinas via fluorescence microscopy. Lipofuscin autofluorescence was separately evaluated in four regions of the retina, defined according to the known cone density [fig. S3 and (6)]; measurements were done in 8.5-month-old (n = 2; i.e., 63OD and 65OD), 10-month-old (n = 6; i.e., 7OD, 7OS, 14OD, 14OS, 15OD, and 15OS), and 15-month-old (n = 2; i.e., 731OD and 731OS) KO eyes; WT: average lipofuscin levels from n = 6 eyes (i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS). m.o., month-old. (D) A2E levels in KO pig RPE; measurements were done in 10- to 15-month-old WT (n = 6; i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS) and KO (n = 8; 7OD, 7OS, 14OD, 14OS, 15OD, 15OS, 731OD, and 731OS) eyes. ***P < 0.001, Welch’s t test. (E) Quantification of ONL thickness in the four retinal regions of KO pig eyes. Measurements were done in 8.5-month-old (n = 2; i.e., 63OD and 65OD), 10–10.5-month-old (n = 8; i.e., 6OD, 7OD, 7OS, 12OD, 14OD, 14OS, 15OD, and 15OS), and 15-month-old (n = 2; i.e., 731OD and 731OS) KO eyes; WT: average levels from n = 6 eyes (i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS). (F) Measurements of retinal electrical activity via ERG analysis in KO pigs at 2 to 3 years of age. *P < 0.05, Welch’s t test. [(C) to (F)] Data are presented as average ± SEM. Each dot represents a retina.
Fig. 1. Characterization of the STGD1 pig model. (A) Western blot analysis to assess ABCA4 levels in STGD1 (KO) pig retinas derived from different fibroblasts clones. The ID of the clones is indicated above each lane. WT, wild-type. (B) Representative images of retinal cryosections from WT and KO pigs at 10 months of age, showing intense lipofuscin accumulation (red autofluorescence in the RPE layer), in the absence of evident retinal degeneration. RPE, retinal pigment epithelium; ONL, outer nuclear layer; INL, inner nuclear layer. (C) Quantification of lipofuscin accumulation in KO pig retinas via fluorescence microscopy. Lipofuscin autofluorescence was separately evaluated in four regions of the retina, defined according to the known cone density [fig. S3 and (6)]; measurements were done in 8.5-month-old (n = 2; i.e., 63OD and 65OD), 10-month-old (n = 6; i.e., 7OD, 7OS, 14OD, 14OS, 15OD, and 15OS), and 15-month-old (n = 2; i.e., 731OD and 731OS) KO eyes; WT: average lipofuscin levels from n = 6 eyes (i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS). m.o., month-old. (D) A2E levels in KO pig RPE; measurements were done in 10- to 15-month-old WT (n = 6; i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS) and KO (n = 8; 7OD, 7OS, 14OD, 14OS, 15OD, 15OS, 731OD, and 731OS) eyes. ***P < 0.001, Welch’s t test. (E) Quantification of ONL thickness in the four retinal regions of KO pig eyes. Measurements were done in 8.5-month-old (n = 2; i.e., 63OD and 65OD), 10–10.5-month-old (n = 8; i.e., 6OD, 7OD, 7OS, 12OD, 14OD, 14OS, 15OD, and 15OS), and 15-month-old (n = 2; i.e., 731OD and 731OS) KO eyes; WT: average levels from n = 6 eyes (i.e., 707OD, 707OS, 850OD, 850OS, 857OD, and 857OS). (F) Measurements of retinal electrical activity via ERG analysis in KO pigs at 2 to 3 years of age. *P < 0.05, Welch’s t test. [(C) to (F)] Data are presented as average ± SEM. Each dot represents a retina.CC BY · PubMed Central
Fig. 2. AAV8.ABCA4.intein mediated gene therapy in STGD1 pigs. (A) Western blot (WB) analysis on retinal lysates from both FB-injected WT eyes and from STGD1 pig (KO) eyes either injected with AAV8.ABCA4.intein vectors or with FB. Further details on the areas of the retina used for the WB are provided in fig. S4. The anti-ABCA4 antibody used in the WB reacts with both human (expressed from AAV8.ABCA4.intein vectors; dashed arrow) and swine (i.e., endogenous in WT; straight arrow) ABCA4. (B) Representative images of retinal cryosections from FB-treated WT (top), FB-treated KO (middle), and AAV8.ABCA4.intein injected KO (bottom) eyes. RPE, retinal pigment epithelium; ONL, outer nuclear layer. (C) Quantification of lipofuscin accumulation in the area with highest levels of transduction in AAV8.ABCA4.intein-treated eyes (2 months postinjection), expressed as ratio relative to the same area in contralateral FB-treated eyes. Light gray bars represent average values (± SEM) of measurements taken in the three AAV8.ABCA4.intein-treated KO eyes (pig ID is reported below the graph). The dark gray bar represents average values (± SEM) of measurements taken in the three contralateral FB-treated KO eyes. Dots represent single measurements in each retinal section. Data were analyzed using one-way ANOVA followed by Dunnett’s test, *P < 0.05.
Fig. 2. AAV8.ABCA4.intein mediated gene therapy in STGD1 pigs. (A) Western blot (WB) analysis on retinal lysates from both FB-injected WT eyes and from STGD1 pig (KO) eyes either injected with AAV8.ABCA4.intein vectors or with FB. Further details on the areas of the retina used for the WB are provided in fig. S4. The anti-ABCA4 antibody used in the WB reacts with both human (expressed from AAV8.ABCA4.intein vectors; dashed arrow) and swine (i.e., endogenous in WT; straight arrow) ABCA4. (B) Representative images of retinal cryosections from FB-treated WT (top), FB-treated KO (middle), and AAV8.ABCA4.intein injected KO (bottom) eyes. RPE, retinal pigment epithelium; ONL, outer nuclear layer. (C) Quantification of lipofuscin accumulation in the area with highest levels of transduction in AAV8.ABCA4.intein-treated eyes (2 months postinjection), expressed as ratio relative to the same area in contralateral FB-treated eyes. Light gray bars represent average values (± SEM) of measurements taken in the three AAV8.ABCA4.intein-treated KO eyes (pig ID is reported below the graph). The dark gray bar represents average values (± SEM) of measurements taken in the three contralateral FB-treated KO eyes. Dots represent single measurements in each retinal section. Data were analyzed using one-way ANOVA followed by Dunnett’s test, *P < 0.05.CC BY · PubMed Central
Fig. 3. Intraocular inflammation and electroretinography (ERG) responses upon AAV8.ABCA4.intein subretinal administration in NHPs. (A) Aqueous cells, aqueous flare, and vitreous cells were monitored in injected eyes at different time points postinjection. A score (from 1 to 4) was attributed to define the severity of the ocular findings in each eye. White bars: formulation buffer–treated eyes (FB); light gray bars: eyes treated with a low dose of AAV8.ABCA4.intein vectors (LD); dark gray bars: eyes treated with a high dose of AAV8.ABCA4.intein vectors (HD). Bars represent average values ± SEM for each group. Detailed number of eyes analyzed and values measured in each eye at each time point are presented in fig. S6. (B) ERG values in right eyes treated with either an LD or an HD of AAV8.ABCA4.intein vectors are expressed as percentage relative to left FB-treated eyes. Data are presented as means ± SEM. Each dot represents one eye. Pre, analysis performed before injection; w, weeks postinjection. Statistical comparisons were performed using the two-way ANOVA followed by Tukey’s post hoc, *P < 0.05. Further details on statistical analysis, including exact P values, can be found in table S7.
Fig. 3. Intraocular inflammation and electroretinography (ERG) responses upon AAV8.ABCA4.intein subretinal administration in NHPs. (A) Aqueous cells, aqueous flare, and vitreous cells were monitored in injected eyes at different time points postinjection. A score (from 1 to 4) was attributed to define the severity of the ocular findings in each eye. White bars: formulation buffer–treated eyes (FB); light gray bars: eyes treated with a low dose of AAV8.ABCA4.intein vectors (LD); dark gray bars: eyes treated with a high dose of AAV8.ABCA4.intein vectors (HD). Bars represent average values ± SEM for each group. Detailed number of eyes analyzed and values measured in each eye at each time point are presented in fig. S6. (B) ERG values in right eyes treated with either an LD or an HD of AAV8.ABCA4.intein vectors are expressed as percentage relative to left FB-treated eyes. Data are presented as means ± SEM. Each dot represents one eye. Pre, analysis performed before injection; w, weeks postinjection. Statistical comparisons were performed using the two-way ANOVA followed by Tukey’s post hoc, *P < 0.05. Further details on statistical analysis, including exact P values, can be found in table S7.CC BY · PubMed Central
Fig. 4. High levels of retinal transduction following subretinal delivery of AAV8.ABCA4.intein vectors in NHPs. (A) Representative pictures of retinal sections analyzed by BaseScope from NHP eyes at 13 weeks postinjection of either an LD (n = 3) or HD (n = 3) of AAV8.ABCA4.intein vectors or the FB (n = 6). Probes annealing to either the Npu N-intein (dark green dots) or C-intein (red dots) of human.ABCA4.intein mRNAs were used to assess transduction. ONL, outer nuclear layer. (B) ABCA4 protein levels were measured by Simple Western analysis in two retina punches [one superior temporal (black dot) and one superior nasal (gray dot) punch] collected from the injected bleb area of eyes receiving either a subretinal injection of AAV8.ABCA4.intein at the LD (n = 2) or HD (n = 2) or FB (n = 1) as control. ABCA4 protein levels were normalized to the endogenous control (PDE6B) and then expressed as percentage (%) of ABCA4 protein levels in AAV8.ABCA4.intein-treated versus FB-treated areas. Columns represent mean values for group of treatment, whereas dots represent value of each retina punch. Data are reported as means ± SEM.
Fig. 4. High levels of retinal transduction following subretinal delivery of AAV8.ABCA4.intein vectors in NHPs. (A) Representative pictures of retinal sections analyzed by BaseScope from NHP eyes at 13 weeks postinjection of either an LD (n = 3) or HD (n = 3) of AAV8.ABCA4.intein vectors or the FB (n = 6). Probes annealing to either the Npu N-intein (dark green dots) or C-intein (red dots) of human.ABCA4.intein mRNAs were used to assess transduction. ONL, outer nuclear layer. (B) ABCA4 protein levels were measured by Simple Western analysis in two retina punches [one superior temporal (black dot) and one superior nasal (gray dot) punch] collected from the injected bleb area of eyes receiving either a subretinal injection of AAV8.ABCA4.intein at the LD (n = 2) or HD (n = 2) or FB (n = 1) as control. ABCA4 protein levels were normalized to the endogenous control (PDE6B) and then expressed as percentage (%) of ABCA4 protein levels in AAV8.ABCA4.intein-treated versus FB-treated areas. Columns represent mean values for group of treatment, whereas dots represent value of each retina punch. Data are reported as means ± SEM.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 0 Not valid · 12 Not checked · 73 Own results and interpretations

55 more claims

Create a free account to see all 92 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 21
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 1

  1. E. R. Burnight, L. A. Wiley, D. Ochoa, K. Varzavand, S. Seo, I. Han, R. F. Mullins, E. M. Stone, B. A. Tucker, A dual AAV vector approach for the treatment of ABCA4-associated retinal disease. Invest. Ophthalmol. Vis. Sci. 65, 1540–1540 (2024).

Cited by

See all 19

Metadata

Authors
Ferla, R., Pugni, E., Lupo, M., Tiberi, P., Fioretto, F., Perota, A., Duchi, R., Lagutina, I., Gesualdo, C., Rossi, S., Ventrella, D., Elmi, A., McClinton, B., Toomes, C., Xu, T., Molday, R. S., Surace, E. M., Simonelli, F., Bacci, M. L., Galli, C., Memon, M. A., Shams, N., Auricchio, A., & Trapani, I.
Affiliations
  • AAVantgarde Bio srl, Milan, Italy.
  • Telethon Institute Of Genetics And Medicine (IT)
  • Federico II University Hospital (IT)
  • Avantea (IT)
  • University of Campania "Luigi Vanvitelli" (IT)
  • University of Bologna (IT)
  • University of Pisa (IT)
  • University of Leeds (GB)
  • University of British Columbia (CA)
Corresponding author
Trapani, Ivana
Venue
Science Advances
Published
2025-03-28
Volume
11
Issue
13
Pages
eadt9354-eadt9354
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4408865117
Cited by
19
References
25
Citations by year
2026: 15 · 2025: 4
FWCI
5.67
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
Fondazione Telethon
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
Stargardt disease, STGD1, retinal gene therapy, adeno-associated virus vectors, subretinal gene delivery, porcine model, lipofuscin accumulation, macular dystrophy, phototransduction, inflammation, large animal model, non-human primates, gene therapy safety
MeSH terms
Stargardt Disease, Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Macular Degeneration, Retina, Swine, Genetic Therapy, Inteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.